Tris(1,3-dichloro-2-propyl)phosphate is a clear colorless viscous liquid. Generally a super-cooled liquid at room temperature but may occasionally solidify when held at low temperatures for prolonged periods. (NTP, 1992)
颜色/状态：
Viscous liquid
气味：
Mild odor
蒸汽压力：
2.86X10-7 mm Hg at 25 °C (est)
稳定性/保质期：
Resistant to chlorination in aqueous soln; it has an extremely low rate of hydrolysis & resists attack by bases.
自燃温度：
955 °F (NTP, 1992)
分解：
Tris(1,3-dichloro-2-propyl) phosphate was subjected to thermal oxidative degradation in air at 370 °C, hydrogen halides and halogenated C2- and C3-species resulted, acrolein presented the major toxic hazard.
Five days after iv admin of (14)C-tris(1,3-dichloro-2-propyl) phosphate to Sprague-Dawley rats, 22% was excreted in expired air as (14)CO2. Major urinary, fecal, and biliary metabolite was bis(1,3-dichloro-2-propyl)phosphate. Other metabolites include the mono ester, 1,3-dichloro-2-propyl phosphate, and 1,3-dichloro-2-propanol.
Tris(1,3-dichloro-2-propyl)phosphate (Tris-CP) was metabolized to products which were mutagenic for Salmonella typhimurium TA100 in the presence of liver microsomes from phenobarbital (PB) pretreated rats and reduced nicotinamide adenine dinucleotide. ...
TDCPP was rapidly metabolized in vitro by an NADPH-dependent microsomal mixed-function oxidase system & glutathione S-transferases from rat liver to BDCPP, 1,3-dichloro-2-propanol, 3-chloro-1,2-propanediol, & one metabolite which was probably a glutathione conjugate.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
毒性数据
大鼠LC50 > 5,220毫克/立方米/4小时
LC50 (rat) > 5,220 mg/m3/4h
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
解毒与急救
/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最小流量/。如果出现低血容量的迹象，使用0.9%的生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
/HUMAN EXPOSURE STUDIES/ Organophosphate (OP) compounds, such as tris(1,3-dichloro-2-propyl) phosphate (TDCPP) and triphenyl phosphate (TPP), are commonly used as additive flame retardants and plasticizers in a wide range of materials. ... /Researchers/ explored relationships of TDCPP and TPP concentrations in house dust with hormone levels and semen quality parameters. /They/ analyzed house dust from 50 men recruited through a U.S. infertility clinic for TDCPP and TPP. Relationships with reproductive and thyroid hormone levels, as well as semen quality parameters, were assessed using crude and multivariable linear regression. TDCPP and TPP were detected in 96% and 98% of samples, respectively, with widely varying concentrations up to 1.8 mg/g. In models adjusted for age and body mass index, an interquartile range (IQR) increase in TDCPP was associated with a 3% [95% confidence interval (CI), 5% to 1%) decline in free thyroxine and a 17% (95% CI, 432%) increase in prolactin. There was a suggestive inverse association between TDCPP and free androgen index that became less evident in adjusted models. ... OP flame retardants may be associated with altered hormone levels and decreased semen quality in men. ...
C-labeled Fyrol FR-2 was readily absorbed from skin and GI tract of rats and rapidly distributed throughout body. Route of admin had little effect on distribution. Absorption and distribution were unaffected over dose range of 2 orders of magnitude.
Six hr after admin (94.4 umol/kg, iv) of u-(14)C-labeled tris(1,3-dichloro-2-propyl) phosphate, there were varying amt in liver, kidney, muscle, nucleic acids, and protein isolated from each tissue. Highest concn in liver. In each tissue, highest concn of bound radioactivity was in low mol wt RNA, with decr concn in protein, RNA, and DNA.
Five days after iv admin of (14)C-tris(1,3-dichloro-2-propyl) phosphate (TDCP) to sprague dawley rats, 92% of admin radiolabel was excreted; 54% in urine, 16% in feces, & 22% in expired air; 4% was recovered in the body. Less than 0.1% of admin dose was recovered as tris(1,3-dichloro-2-propyl) phosphate in excreta. TDCP was eliminated primarily by rapid metabolism whereas the slowly metabolized bis(1,3-dichloro-2-propyl)phosphate was eliminated by excretion. Major portion of radiolabel excreted in bile underwent enterohepatic recirculation.
In continuous flow test system tris(1,3-dichloro-2-propyl) phosphate was taken up rapidly by killifish reaching max on 1st day & levels were maintained until last day of exposure. Elimination was very fast.
AMIDINE GROUP - OR GUANIDINE GROUP - CONTAINING SILANE
申请人：SIKA TECHNOLOGY AG
公开号：US20170081348A1
公开（公告）日：2017-03-23
A silane of the formula (I) containing at least one aliphatic amidine group- or guanidine group-containing alkoxy group, to a method for producing same, to conversion products thereof, and to the use thereof as a catalyst in curable compositions, in particular based on silane group-containing polymers. The silane of the formula (I) is largely odorless and non-volatile at room temperature. The silane accelerates the hydrolysis and condensation reaction of silane groups very effectively without impairing the storage stability of silane group-containing polymers. Additionally, the silane is very tolerable in silane group-containing compositions, whereby such compositions are not prone to separate, migrate, or evaporate the catalyst.
HYDROXYSILANE AND POLYMER CONTAINING SILANE GROUPS
申请人：SIKA TECHNOLOGY AG
公开号：US20160102110A1
公开（公告）日：2016-04-14
Special hydroxysilanes, which can be obtained by reacting β-(3,4-epoxycyclohexyl)alkyltrialkoxysilanes with secondary amines, and adducts of the hydroxysilanes in the form of polymers containing silane groups. The hydroxysilanes can be produced having high purity in a simple process and are very stable in storage after production. The polymers containing silane groups that can be obtained by means of the hydroxysilanes have advantageous properties. The polymers enable moisture-curing compositions, which contain no isocyanate groups and which are suitable as elastic adhesives and sealants.
Hydrocarbyl terminated polyester compounds comprising sulfur-containing repeat units that are useful as plastic modifiers, polymer blend compositions comprising the hydrocarbyl terminated polyester compounds, methods for modifying the performance properties of polymers, and methods for preparing the hydrocarbyl terminated polyester compounds.
The present disclosure invention relates to novel secondary aminosilanes, a method for producing same, and the use thereof. The secondary aminosilanes can be produced from readily available reactants in a simple manner. The secondary aminosilanes are characterized for example by a low viscosity and are well suited for producing silane-functional polymers that have a low viscosity, fast curing, and good thermal stability.
LATENT CURING AGENT AND CURABLE POLYURETHANE COMPOSITION
申请人：SIKA TECHNOLOGY AG
公开号：US20200140599A1
公开（公告）日：2020-05-07
A compound of formula (I) having advantageous properties when used as a latent curing agent for compositions containing isocyanate groups, and to compositions containing the compound of formula (I). The compound of formula (I) is odourless, is liquid and has comparatively low viscosity at room temperature and is stable in storage together with isocyanates. It makes possible odourless single-component polyurethane compositions which have good stability in storage, do not produce bubbles when cured in the presence of moisture, and cause no problematic odour emissions, giving a cured elastic material having good mechanical properties, good heat stability, a surprisingly non-adhesive surface and little tendency towards plasticizer migration.
